

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

INSIDE INFORMATION
ISSUANCE OF THE 2023 FIRST TRANCHE OF SUPER & SHORT TERM
COMMERCIAL PAPER AND MEDIUM TERM NOTES
AT THE NATIONAL ASSOCIATION OF FINANCIAL MARKET
INSTITUTIONAL INVESTORS

This announcement is made by China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 18 February 2022 in relation to the issuance (the “**Issue**”) of a Super & Short-term Commercial Paper in the aggregate amount of RMB2.8 billion and a medium term notes with an aggregated amount of RMB2.2 billion (the “**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company proceeds with the renewal of the Issue. On 18 to 19 May 2023, the Company had completed the issuance of the 2023 first tranche of Super & Short-term Commercial Paper and medium term notes, for an aggregate amount of RMB1 billion and RMB1.2 billion, respectively, with a maturity of 200 days and coupon rate of 2.3% per annum for the Super & Short-term Commercial Paper and a maturity of three years and coupon rate of 3.04% per annum for the medium term notes. The proceeds from this issuance are intended to be used for the repayment of RMB2.2 billion medium term notes which will be matured on 5 June 2023.

A memorandum containing information of the Issue has been disclosed on the website of China Money (<http://www.chinamoney.com.cn/>) and Shanghai Clearing House (<http://www.shclearing.com.cn/>).

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
CHEN Yinglong
Chairman

Hong Kong, 24 May 2023

As at the date of this announcement, the Board comprises twelve directors, of which Mr. CHEN Yinglong, Mr. CHENG Xueren and Mr. YANG Wenming are executive directors; Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan, Mr. MENG Qingxin and Mr. KUI Kaipin are non-executive directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive directors.